Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project

Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry: Table 1

(2016) Suzanne V. Arnold et al.   DIABETES CARE

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

(2016) Muhammad Abdul-Ghani et al.   DIABETES CARE

8. Pharmacologic Approaches to Glycemic Treatment

(2016)   DIABETES CARE

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Capacity of Evidence to Inform Practice

(2015) Thomas M. Maddox et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

(2011) Tina Ken Schramm et al.   EUROPEAN HEART JOURNAL

Cause-specific mortality in diabetes: recent changes in trend mortality

(2011) Charbel Abi Khalil et al.   European Journal of Preventive Cardiology